checkAd

     376  0 Kommentare Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference

    GAITHERSBURG, Md., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 11:00 a.m. ET in New York, NY at The New York Palace Hotel.

    A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.

    About Novavax

    Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

    CONTACT: Barclay A. Phillips
             SVP, Chief Financial Officer and Treasurer
             Novavax, Inc.
             240-268-2000



    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novavax, Inc. via Globenewswire

    HUG#1874373


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will …

    Schreibe Deinen Kommentar

    Disclaimer